JP2015524821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524821A5 JP2015524821A5 JP2015525568A JP2015525568A JP2015524821A5 JP 2015524821 A5 JP2015524821 A5 JP 2015524821A5 JP 2015525568 A JP2015525568 A JP 2015525568A JP 2015525568 A JP2015525568 A JP 2015525568A JP 2015524821 A5 JP2015524821 A5 JP 2015524821A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fusion protein
- human
- disulfide bond
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000037865 fusion proteins Human genes 0.000 claims 25
- 108020001507 fusion proteins Proteins 0.000 claims 25
- 235000018417 cysteine Nutrition 0.000 claims 6
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 150000001945 cysteines Chemical class 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102000009058 Death Domain Receptors Human genes 0.000 claims 1
- 108010049207 Death Domain Receptors Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 101710165202 T-cell surface antigen CD2 Proteins 0.000 claims 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 1
- 108700012411 TNFSF10 Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679045P | 2012-08-02 | 2012-08-02 | |
| US61/679,045 | 2012-08-02 | ||
| US201361767724P | 2013-02-21 | 2013-02-21 | |
| US61/767,724 | 2013-02-21 | ||
| PCT/US2013/053086 WO2014022592A1 (en) | 2012-08-02 | 2013-07-31 | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524821A JP2015524821A (ja) | 2015-08-27 |
| JP2015524821A5 true JP2015524821A5 (enExample) | 2016-08-25 |
Family
ID=50025683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525568A Withdrawn JP2015524821A (ja) | 2012-08-02 | 2013-07-31 | システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9540442B2 (enExample) |
| EP (1) | EP2880057A4 (enExample) |
| JP (1) | JP2015524821A (enExample) |
| CN (1) | CN104684928A (enExample) |
| CA (1) | CA2879814A1 (enExample) |
| IN (1) | IN2015DN01361A (enExample) |
| WO (1) | WO2014022592A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008022349A2 (en) | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| CA2694762A1 (en) | 2007-07-27 | 2009-02-05 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| HUE044865T2 (hu) | 2009-10-09 | 2019-11-28 | Armagen Inc | Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére |
| WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| AU2013259276B2 (en) | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| EP2880057A4 (en) | 2012-08-02 | 2016-03-23 | Jn Biosciences Llc | MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL |
| AU2015226101B2 (en) * | 2014-03-05 | 2019-08-22 | Ucb Biopharma Sprl | Multimeric Fc proteins |
| BR112016020368A2 (pt) | 2014-03-05 | 2018-01-23 | Ucb Biopharma Sprl | proteínas fc multiméricas |
| CA2944647C (en) | 2014-04-03 | 2025-07-08 | Igm Biosciences Inc | MODIFIED J STRING |
| SMT202100116T1 (it) | 2014-05-28 | 2021-05-07 | Agenus Inc | Anticorpi anti-gitr e metodi di utilizzo degli stessi |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| HUE052182T2 (hu) * | 2014-12-19 | 2021-04-28 | Jiangsu Hengrui Medicine Co | Interleukin 15 fehérjekomplex és annak felhasználása |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| US10689449B2 (en) * | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| IL297997A (en) * | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| AU2016246695A1 (en) * | 2015-04-07 | 2017-10-26 | Genentech, Inc. | Antigen binding complex having agonistic activity and methods of use |
| CA2983034A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| TWI716405B (zh) | 2015-05-07 | 2021-01-21 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
| US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| HUE069387T2 (hu) | 2015-09-30 | 2025-03-28 | Igm Biosciences Inc | Módosított J-lánccal rendelkezõ kötõmolekulák |
| WO2017075484A2 (en) | 2015-10-30 | 2017-05-04 | Galaxy Biotech, Llc | Highly potent antibodies binding to death receptor 4 and death receptor 5 |
| TWI778491B (zh) | 2015-11-30 | 2022-09-21 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| TWI703160B (zh) * | 2015-11-30 | 2020-09-01 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| SG11201805422WA (en) * | 2016-01-11 | 2018-07-30 | Inhibrx Inc | Multivalent and multispecific ox40-binding fusion proteins |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
| EP3455243B1 (en) | 2016-05-11 | 2021-03-24 | Cytiva BioProcess R&D AB | Separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| WO2018017761A1 (en) * | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
| AU2017299610B2 (en) * | 2016-07-20 | 2022-09-29 | Igm Biosciences, Inc. | Multimeric CD40 binding molecules and uses thereof |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| CN119390821A (zh) | 2017-08-15 | 2025-02-07 | 伊兰科美国公司 | 兽药用IgG Fc变体 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| IL321773A (en) | 2017-10-14 | 2025-08-01 | Cytomx Therapeutics Inc | Activatable antibodies and methods for preparing them |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210009711A1 (en) | 2018-03-14 | 2021-01-14 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| KR20210009421A (ko) | 2018-06-14 | 2021-01-26 | 바이오아트라, 엘엘씨 | 다중 특이적 항체 구조체 |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| KR102232659B1 (ko) * | 2018-07-16 | 2021-03-26 | 전북대학교 산학협력단 | 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도 |
| KR20210044243A (ko) | 2018-08-13 | 2021-04-22 | 인히브릭스, 인크. | Ox40 결합 폴리펩티드 및 이의 용도 |
| MX2021007680A (es) * | 2018-12-27 | 2021-10-13 | Kindred Biosciences Inc | Variantes de igg fc para uso veterinario. |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| CA3131016A1 (en) | 2019-02-21 | 2020-08-27 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020172598A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| GB2598218B (en) | 2019-02-21 | 2024-05-08 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| KR20230028242A (ko) | 2020-04-24 | 2023-02-28 | 마렝고 테라퓨틱스, 인크. | T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도 |
| CA3190766A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| GB2616354A (en) | 2020-08-26 | 2023-09-06 | Marengo Therapeutics Inc | Methods of detecting TRBC1 or TRBC2 |
| WO2022045865A1 (ko) | 2020-08-31 | 2022-03-03 | (주)메디톡스 | 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물 |
| KR20220029343A (ko) | 2020-08-31 | 2022-03-08 | (주)메디톡스 | 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물 |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| WO2022232246A1 (en) * | 2021-04-28 | 2022-11-03 | Ngm Biopharmaceuticals, Inc. | Multimerization of binding molecules having an antibody constant region variant |
| CN115724985A (zh) * | 2021-08-27 | 2023-03-03 | 三生国健药业（上海）股份有限公司 | 一种cdc平台抗体 |
| GB202319645D0 (en) * | 2023-12-20 | 2024-01-31 | Kbio Holdings Ltd | Hexameric protein |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020147326A1 (en) * | 1996-06-14 | 2002-10-10 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| GB9720054D0 (en) * | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
| US6475749B1 (en) | 1999-08-11 | 2002-11-05 | The Regents Of The University Of California | Rh hybrid antibody |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| CA2545603A1 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| JPWO2008032833A1 (ja) * | 2006-09-14 | 2010-01-28 | 株式会社医学生物学研究所 | Ａｄｃｃ活性を増強させた抗体及びその製造方法 |
| GB0922209D0 (en) | 2009-12-18 | 2010-02-03 | Univ Nottingham | Proteins, nucleic acid molecules and compositions |
| WO2013049254A1 (en) | 2011-09-26 | 2013-04-04 | Jn Biosciences Llc | Hybrid constant regions |
| EP2880057A4 (en) | 2012-08-02 | 2016-03-23 | Jn Biosciences Llc | MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL |
-
2013
- 2013-07-31 EP EP13825409.9A patent/EP2880057A4/en not_active Withdrawn
- 2013-07-31 US US13/956,121 patent/US9540442B2/en active Active
- 2013-07-31 IN IN1361DEN2015 patent/IN2015DN01361A/en unknown
- 2013-07-31 JP JP2015525568A patent/JP2015524821A/ja not_active Withdrawn
- 2013-07-31 CA CA2879814A patent/CA2879814A1/en active Pending
- 2013-07-31 WO PCT/US2013/053086 patent/WO2014022592A1/en not_active Ceased
- 2013-07-31 CN CN201380041074.3A patent/CN104684928A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524821A5 (enExample) | ||
| JP2015501291A5 (enExample) | ||
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| US20210171661A1 (en) | Production of t cell retargeting hetero-dimeric immunoglobulins | |
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| JP7352973B2 (ja) | 二重特異性抗体及びその使用 | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| CA3113605A1 (en) | Novel bispecific antibodies for use in the treatment of hematological malignancies | |
| SI2699264T1 (en) | Antibodies and other molecules that bind b7-h1 and pd-1 | |
| EP4464333A3 (en) | Anti-death receptor antibodies and methods of use thereof | |
| JP2018518491A5 (enExample) | ||
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| NZ732019A (en) | Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production | |
| HRP20240415T1 (hr) | Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba | |
| HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
| WO2016191246A3 (en) | T cell receptor-like antibodies specific for a prame peptide | |
| JP2013529084A5 (enExample) | ||
| CA3086653A1 (en) | Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa) | |
| CN108463472A (zh) | 具有修饰的j-链的结合分子 | |
| JP2017504578A5 (enExample) | ||
| JP7257971B2 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| CA2990518A1 (en) | Multispecific nk engager proteins | |
| HRP20200918T1 (hr) | Modificirane mutirane fuzijske molekule interferonskog antitijela | |
| AU2012362378A1 (en) | Light chain-bridged bispecific antibody |